Efficacy and safety of rituximab biosimilar in refractory lupus
Aims To characterise patients with refractory SLE receiving rituximab biosimilar (CT-P10) and to explore short-term efficacy and safety associated with rituximab biosimilar use.Methods We retrospectively analysed data from the medical records of patients with refractory SLE who received CT-P10 in Ra...
Saved in:
| Main Authors: | Nantakarn Pongtarakulpanit, Prapaporn Pisitkun, Pintip Ngamjanyaporn |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Lupus Science and Medicine |
| Online Access: | https://lupus.bmj.com/content/7/1/e000442.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Vaginal microbiota affects urinary tract infection risk in women with systemic lupus erythematosus: a pilot cross-sectional study from Thailand
by: Prapaporn Pisitkun, et al.
Published: (2021-04-01) -
No impact of seronegativity on the efficacy of a biosimilar rituximab in biologic-naïve patients with active rheumatoid arthritis
by: Nedumooli Pottammal Jamshid, et al.
Published: (2019-01-01) -
Efficacy and Safety of Rituximab in Lupus Nephritis from a Tertiary Care Rheumatology Clinic in India
by: Manikandan Gopal, et al.
Published: (2024-01-01) -
Rituximab Efficacy during a Refractory Polyarteritis Nodosa Flare
by: Emmanuel Ribeiro, et al.
Published: (2009-01-01) -
Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study
by: Narendra Maharaj, et al.
Published: (2024-12-01)